Cases of extensively drug-resistant shigella infections rose from 0% in 2011 to 8.5% in 2023, according to an April 9 CDC brief.
Shigellosis is a diarrheal illness caused by bacteria that is spread through fecal-oral transmission and sexual contact. Antibiotics are indicated for severe illness or to reduce high-risk for spread, though most cases are self-limited. Currently, there are no FDA-approved oral treatments available.
The CDC analyzed 16,788 isolated cases submitted to PulseNet between Jan. 1, 2011, and Oct. 20, 2023. Previous outbreaks of the drug-susceptible strains primarily affected children, but new data shows the drug-resistant cases mostly occurred in adults. The median age was 41 and 86.2% were men. Approximately one-third of patients were hospitalized.
All of this makes Shigella a public health threat, the brief said.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
